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Abstract
Background: The use of carotid intima-media thickness (carotid IMT) as a surrogate marker of cardiovascular
disease is increasing and the method has now also been applied in several trials investigating patients with type 2
diabetes (T2D). Even though knowledge about methodology is of highest importance in order to make accurate
power calculations and analyses of results, no reproducibility studies have been performed in this group of
patients. The aim of this study was to quantify the variability of the measurement of carotid IMT in individuals with
and without T2D.
Methods: We used B-mode ultrasound and a computerized software programme (MIA vascular tools) for analysis
of carotid IMT. Measurement of carotid IMT in the far wall of the common carotid artery (CCA) was done for 30
patients with T2D and 30 persons without T2D. The examinations were done by two different sonographers and
two different readers on two separate days in order to quantify sonographer-, reader-, and day-to-day variability.
Results: Comparisons of measurement of carotid IMT in CCA between sonographers (sonographer variability)
resulted in limits of agreement (LoA) from -0.18 to 0.13 mm for patients with T2D and -0.12 to 0.10 mm for
persons without T2D. This means, that a second scanning of the same person with 95% probability would be
within this interval of the first scanning. Comparisons between readers assessing the same scanning (reader
variability) resulted in LoA from -0.05 to 0.07 mm and -0.04 to 0.05 mm respectively. LoA of the day-to-day
variability was -0.13 to 0.18 mm and -0.09 to 0.18 mm respectively. This corresponds to coefficients of variations
(CV) of the sonographer- and day-to-day variability of 10% in patients with T2D and 8% in persons without T2D.
The CV of the reader variability was 4% and 3% respectively.
Conclusion: Measurement of carotid IMT in the CCA can be determined with good and comparable
reproducibility in both patients with T2D and persons without T2D. These findings support the use of carotid IMT
in clinical trials with T2D patients and suggest that the numbers of patients needed to detect a given difference
will be the same whether the patients have T2D or not.
Background
Determination of carotid intima-media thickness (caro-
tid IMT) is a generally accepted research method for
detection and quantification of subclinical cardiovascular
disease (CVD). It is based on the combined thickness of
the tunica intima and tunica media of the carotid artery
wall and is measured by B-mode ultrasound. A number
of epidemiological studies reports that increased carotid
IMT is a good predictor of future CVD such as myocar-
dial infarction, stroke and death from CVD. Further-
more carotid IMT correlates well with clinically
established CVD and the Framingham Score[1-5]. Based
on the existing evidence from trials with statins, carotid
IMT fulfils the three generally accepted requirements
for a surrogate marker[6]. In addition, the measurement
is non-invasive, inexpensive, readily applicable and car-
ries virtually no risk for the patient. Therefore, carotid
IMT has now become an established surrogate marker
of CVD in clinical trials to evaluate the efficacy of inter-
ventions with statins, antihypertensives, aspirin and
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of using a surrogate marker instead of hard outcome
measures such as myocardial infarction, stroke and
death are smaller study populations, shorter study dura-
tion and thereby reduced financial costs.
In general, knowledge about research methodology is
of highest importance and as stated by Fleiss in 1986
“The most elegant design of a clinical study will not
overcome the damage caused by unreliable or imprecise
measurements”[13]. This applies obviously also to mea-
surement of carotid IMT. The technique, by which caro-
tid IMT is determined, consists of two steps: The first
step is the “scanning procedure” i.e. ultrasound scanning
of the carotid artery, with storage of pictures/dynamic
sequences and the second step is the “reading proce-
dure” i.e. the following measurement of carotid IMT
using a specialized software technique. Even though the
variability of the technique like this is influenced by
both the scanning procedure and by the following read-
ing procedure, many reproducibility studies have only
taken the variability of the reading procedure into
account which does not reflect the total variability
[14-16]. Furthermore, no methodological studies have
explicitly evaluated the reproducibility in patients with
type 2 diabetes (T2D) even though the method has now
also been increasingly applied in clinical trials with dia-
betes patients [10-12,17-19].
Patients with T2D have a two to fourfold increased
incidence of CVD compared to persons without diabetes
[20,21], which is also reflected by an increased carotid
IMT in T2D patients [22-24]. Earlier studies have sug-
gested that the variability of the measurement of carotid
IMT increases with increasing carotid IMT[25]. Hence,
it could be argued that the variability is increased in
T 2 Dp a t i e n t sc o m p a r e dt op e r s o n sw i t h o u tT 2 D ,b u t
this has not been assessed systematically.
The purpose of this study was to quantify the variabil-
ity between sonographers, between readers and between
days of the measurement of carotid IMT in the far wall
of the common carotid artery (CCA) in patients with
T2D and persons without T2D.
Methods
Patients
Sixty persons participated in this study; 30 patients with
T2D and 30 persons without T2D.
Visits
All participants paid two visits within two weeks (visit A
and B) at Steno Diabetes Center, Copenhagen, Den-
mark. At each visit patients were scanned by two differ-
ent sonographers (sonographer X and Y), to enable
assessment of the day-to-day variability and the sono-
grapher variability (table 1).
Scanning procedure
After 10 minutes of rest in a supine position blood pres-
sure was measured at the left upper arm whereupon the
scanning was performed using a General Healthcare (GE)
logic 9 with a 9 linear (8 MHz) or a 12 linear (12 MHz)
probe. The choice of probe depended on the most appro-
priate probe to the person; however, the same probe with
the same frequency was used for the same person at
every scanning. All examinations were carried out in a
dark, quiet and temperature-controlled room.
With the head in a slightly bended position towards
t h eo p p o s i t es i t eo ft h eo n eb e i n gs c a n n e dt h eu l t r a -
sound transducer was placed in an angle of 90° of the
vessel wall (to obtain parallel ecco lines of the intima
and media in both near and far wall). First a rough
cross sectional scanning was made from the proximal
part of common carotid artery (CCA) throughout the
bifurcation to the internal carotid artery and the exter-
nal carotid artery to localise possible plaques or ste-
noses. The transducer was turned and a longitudinal
scanning was made in the CCA with storage of the
dynamic sequence for the following reading procedure
to measure carotid IMT. The depth of the scan was
adjusted and the transmit focus zone set at the optimal
level to show the best possible image of the far wall of
the CCA. A segment of the artery was magnified using a
r e s o l u t i o nb o xa n dt h eg r e ys c a l ei m a g ea d j u s t e dt o
identify a distinct lumen-intima and media-adventitia
interface of the artery wall. Then, 5 seconds of the ultra-
sound image was digitally recorded on a computer for
later measurements of the carotid IMT. This procedure
Table 1 Scanning and reading procedure for every
participant for the measurement of mean carotid IMT
Visit Sonographer Reader Replicate
AX x 1
x2
y1
y2
Yx 1
x2
y1
y2
BX x 1
x2
y1
y2
Yx 1
x2
y1
y2
Every participant performed two visits (A and B). At every visit they were
scanned twice by each of the sonographers X and Y, and every scanning was
read twice (replicate 1 and 2) by each of the two readers (x and y).
Lundby-Christensen et al. Cardiovascular Diabetology 2010, 9:40
http://www.cardiab.com/content/9/1/40
Page 2 of 7was made first on the right CCA and afterwards on the
left CCA.
Reading procedure
For the border detection and calculation of the carotid
IMT, we used specialized software (vascular tools 5, Medi-
cal Imaging Applications, Iowa, USA). First, the region of
interest was defined as a segment of the CCA far wall
devoid of focal plaques and spanning 5-10 mm with a cen-
tre 10 mm proximal to the bulb. In this region (= reading
frame) the software identifies the lumen/intima and the
media/adventitia borders and calculates the distance in
between, i.e. the carotid IMT. The resolution of the ultra-
sound picture is 10 pixels/mm. The frequency of the pic-
ture is 15 pictures per second during five seconds. The
final average carotid IMT on a 10 mm segment of the ves-
sel wall is thus based on approximately 600 automated cal-
culations during the 5 seconds. IMT was finally calculated
as the mean IMT of the left and right CCA.
Data
For each patient we obtained four scanning results, two
from each of the two visits (visit A and B, table 1).
Each of these were read twice by each of the two readers
(reader X and y) to measure inter- and intra-reader varia-
bility. The readers (x,y) were the same persons as the
sonographers (X,Y). For each reading, the mean CCA of
the left and right side were summed and averaged to yield
the average mean carotid IMT resulting in a total of 16
values of average mean carotid IMT from each participant,
classified by visit, sonographer, reader and replicate of
reading (table 1). Replicates were considered exchangeable
within each combination of visit, sonographer and reader.
Statistical analysis
We computed limits of agreement (LoA) and made
Bland-Altman plots between all pairs of the 8 combina-
tions of visit, sonographer and reader (figure 1). Repli-
cates were randomly permuted for this comparison.
These analyses were performed separately for measure-
ments on patients with T2D and persons without T2D.
Here we report the uncertainty of the measurements
as standard deviation of the mean absolute difference of
the pairwise comparisons (SD (diff)), LoA on the abso-
lute scale (mm) as well as coefficient of variation (CV)
calculated as the SD of the differences of the log-trans-
formed values. The LoA is the 95% prediction interval
for the difference between results from two different
combinations of visit, sonographer and reader, i.e.t h e r e
is a 95% probability that the difference between two
measurements will be in this interval. Depending on
which combinations of visit, sonographer and reader are
compared, different components of the variations are
included; this is indicated in the Bland-Altman plots too
The study complied with the Declaration of Helsinki
and was approved by the Regional Ethical Committee
(region of Copenhagen journal number H-A-2007-0126).
Results
Of the 60 participants, two were excluded as the values of
carotid IMT could not be obtained because of wide-
spread atherosclerosis/plaques in the CCA. They (a man
and a woman) had both had T2D for more than 15 years
and clinically established CVD. Hence, 58 participants
(28 patients with T2D and 30 persons without T2D) as
characterised in table 2 were included in the analysis.
Mean carotid IMT in the far wall CCA in patients with
T2D was 0.800 ± 0.131 mm (mean ± SD). 50% of the
patients with T2D were diagnosed with microalbuminuria
(albumin-to-creatinin ratio 30-300 mg/g in ≥ two of three
consecutive urine samples). Significantly higher values of
carotid IMT were found in the 14 patients with microal-
buminuria (0.867 mm ± 0.122) as compared to the 14
patients with normoalbuminuria (0.733 mm ± 0.106, p <
0.005) despite no difference in age (62.1 years ± 7.1 vs.
64.7 ± 8.3, p = 0.4) or duration of T2D (15.8 years ± 8.4
vs. 16.9 ± 7.3, p = 0.7). In persons without T2D mean car-
otid IMT was 0.679 ± 0.105 mm. Nearly all patients with
T2D were treated with simvastatin 40 mg (96%) whereas
this was the case for only a very little proportion of the
healthy persons (10%). 96% of the patients with T2D
received antihypertensive treatment in terms of angioten-
sin converting enzyme inhibitors (ACEi, 39%), angiotensin
II receptor blockers (ARB, 54%), b-blockers (11%), diure-
tics (68%) and/or calcium channel blockers (CCB, 32%).
Only two persons without T2D received antihypertensive
treatment (ARB and diuretic respectively). Mean systolic
blood pressure among patients with T2D was 132 ± 19
mmHg compared to 126 ± 13 mmHg among persons
without T2D. Mean diastolic blood pressure was 77 ± 9
mmHg and 77 ± 8 mmHg respectively.
Glucose lowering therapies were given as follows: 11%
received diet only, 25% received oral antidiabetics
(OAD’s, i.e. metformin ± sulfonylurea) only, 64%
received insulin (either long-acting (32%), rapid-acting
(11%) and/or biphasic insulin (32%).
The scatter plots and Bland-Altman plots with LoA
indicated are shown in Figure 1, in blue for healthy per-
sons and red for patients with T2D. Overall, there were
no systematic difference between any of the combina-
tions of day, sonographer and reader.
Variability of measurement of carotid IMT in patients
with T2D
When different scanning results were assessed (sonogra-
pher variability), the LoA were -0.18 to 0.13 mm. This
means, that a second scanning of the same person with
95% probability would be within this interval of the first
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red numbers and lines, sonographer variability marked
by “s”). The SD (diff) was 0.078 mm. When the same
scanning’s were assessed by different readers (reader
variability), the limits of agreement were -0.05 to 0.07
mm and the SD (diff) was 0.030 mm. When comparing
scanning’sm a d eb yt h es a m es o n o g r a p h e ra n dr e a db y
the same reader but assessed on two different days (day-
to-day variability) the limits of agreement were -0.13 to
0.18 mm and the SD (diff) was 0.075 mm (Figure 1).
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Figure 1 Scatter and Bland-Altman plots of the pairwise comparisons of carotid IMT. Measurements of carotid IMT - average of left and
right side measurements on the absolute scale (mm). Comparisons across visits (A/B), sonographers (X/Y) and readers (x/y). Replicate
measurements are randomly permuted within each combination of these three factors. Points and lines in red are for persons with T2D, in blue
for persons without T2D. The panels above the diagonal are Bland-Altman plots of the differences of the pairwise comparisons of carotid IMT.
Plots below the diagonal are just the corresponding scatter plots. Limits of agreement are given in brackets (), red for T2D and blue for persons
without T2D. Visits: A and B, sonographers: X and Y, readers: X and y. Symbols in plot: S = sonographer variability, R = reader variability, D = day-
to-day variability, S + R = combined sonographer and reader variability, S + D = combined sonographer and day-to-day variability, R + D =
combined reader and day-to-day variability, S + R + D = combined sonographer, reader and day-to-day variability.
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without T2D
When different scanning results were assessed (sonogra-
pher variability), the limits of agreement were -0.12 to
0.10 mm and the SD (diff) was 0.055 mm (figure 1).
When the same scanning’s were assessed by different
readers (reader variability), the limits of agreement were
-0.04 to 0.05 mm and the SD (diff) was 0.023 mm.
When comparing scanning’s made by the same sonogra-
pher and read by the same reader but assessed on two
different days (day-to-day variability) the limits of
agreement were -0.09 to 0.18 mm and the SD (diff) was
0.050 mm.
The coefficient of variation (CV) as measured by the
SD of the log-transformed values was 10% between
sonographers and between days (10% for patients with
T2D and 8% for persons without T2D) and 4% between
readers (4% for patients with T2D and 3% for persons
without T2D).
Discussion
The use of carotid IMT has been increasingly used in
trials investigating patients with T2D. The existing
knowledge about reproducibility of this method is based
on very heterogeneously populations including either no
or relatively few patients with T2D[15,16]. With regard
to future clinical diabetes research further knowledge
about reproducibility of this method is required. In this
methodological study we have explicitly evaluated the
reproducibility of the method in patients with T2D and
persons without T2D and we have accurately pointed
out the main sources and sizes of variability. The study
shows that carotid IMT can be determined with good
and comparable reproducibility in both patients with
T2D and healthy persons.
The patients with T2D participating in this study had a
mean diabetes duration of 16 ± 8 years, 50% had microal-
buminuria, 21% had clinical established CVD and the
mean age was 63,4 ± 7,8 years which confirms that we
deal with a group of patients with advanced disease. In
contrast, the persons without T2D were younger (54.4 ±
10,3 years) and had no clinical established CVD. The
main source of variability in the measurement of carotid
IMT was found in the scanning procedure with a CV of
10% and 8% for patients with T2D and persons without
T2D respectively. This variability corresponds well with
the sonographer variability reported in other studies per-
formed in persons without T2D or in some cases appears
to be of even smaller magnitude [25-27]. The day-to-day
variability was identical to the sonographer variability for
both patients with T2D and persons without T2D (CV of
10% and 8% respectively) which likewise is in agreement
with earlier studies in normoglycaemic individuals[28].
Only a minor source of variability was found in the read-
ing procedure (CV of 4% and 3% respectively) as reported
earlier in persons without T2D[16]. So even though the
patients with T2D in this study had an advanced disease,
were approximately 9 years older, had higher BMI, higher
systolic blood pressure and a higher proportion of males,
the variability of the measurement of carotid IMT were
nearly identical to the persons without T2D. It should be
noted, however, that this study only used two sonogra-
phers, so it could be argued, that more sonographers
would increase the sonographer variability. However, as
the variability between scanning results by the same
sonographer from different days (day-to-day variability)
is of the same order of magnitude as the variability
between different sonographers on the same day (sono-
grapher variability), it is unlikely that this would be the
case.
In addition, we found a significant increase in carotid
IMT independent of age and duration of diabetes in the
T2D patients with microalbuminuria compared to the
patients with normoalbuminuria. Accordingly, earlier
studies have found a significant association between car-
otid IMT and diabetic nephropathy measured as either
microalbuminuria (elevated ACR) and/or decreased esti-
mated glomerular filtration rate (eGFR)[29-31].
Table 2 Characteristics of participants (%/mean ± SD)
Patients with
T2D
Persons without
T2D
n2 8 3 0
Age (years) 63.4 ± 7.8 54.4 ± 10.3
Men (%) 68 47
Diabetes duration (years) 16 ± 8 0
Smokers (%) 21 10
BMI (kg/m2) 32.7 ± 4.5 26.4 ± 3.6
Microalbuminuria (%) 50 0
Prevalent CVD (%) 21 0
Total cholesterol (mmol/l) 3.76 ± 0.71 5.10 ± 1.06
HDL cholesterol (mmol/l) 1.33 ± 0.39 1.55 ± 0.33
LDL cholesterol (mmol/l) 1.76 ± 0.57 2.94 ± 0.93
Triglycerides (mmol/l) 1.45 ± 0.55 1.33 ± 0.57
Treatment with statins (%) 96 10
HbA1c (%) 7.75 ± 1.04 5.52 ± 0.22
Therapeutic methods for T2D:
Diet only/OAD/insulin/OAD
+insulin (%)
11/14/50/25
Systolic blood pressure (mmHg) 132 ± 19 126 ± 13
Diastolic blood pressure (mmHg) 77 ± 9 77 ± 8
Antihypertensive treatment (%) 96 7
Therapeutic method for
hypertension:
ACEi/ARB/b-blockers/diuretics/
CCB (%)
39/54/11/68/32 0/3/0/3/0
Mean carotid IMT (mm) 0.800 ± 0.131 0.679 ± 0.105
OAD: Oral antidiabetics, ACEi: angiotensin-converting enzyme inhibitor, ARB:
angiotensin II receptor blocker, CCB: calcium channel blocker
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In conclusion, this study demonstrates that measure-
ment of carotid IMT can be performed in patients with
T2D without markedly increasing the variability of the
m e a s u r e m e n ta sc o m p a r e dt op e r s o n sw i t h o u tT 2 D .
The major source of variability is found in the scanning
procedure, which has nearly identical variability as the
day-to-day variability, whereas very little variability is
found in the following reading procedure.
Thus, given the present results studies using carotid
IMT as outcome will be subject to nearly the same
variability related to methodology whether they are per-
formed in patients with T2D or in persons without.
These results justify the use of carotid IMT in trials
with T2D patients and suggest that the numbers of
patients needed to detect a given difference in a clinical
trial will be the same whether the patients have T2D or
not.
Acknowledgements
We thank Birthe Nielsen and Lotte Pietraszek for their valuable technical
support with the ultrasound scanning and analyses. This study was
supported by a clinical research grant from Steno Diabetes Center A/S,
Gentofte, Denmark.
Author details
1Steno Diabetes Center, Niels Steensens vej 2-4, 2820 Gentofte, Denmark.
2Frederiksberg Hospital, dept. of clinical physiology and nuclear medicine,
Nordre Fasanvej 57-59, 2000 Frederiksberg, Denmark.
Authors’ contributions
LLC, TPA, LT and NW conceived of the study and participated in its design,
coordination and helped to draft the manuscript. BXC participated in the
design, helped to draft the manuscript and performed the statistical
analyses. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 June 2010 Accepted: 20 August 2010
Published: 20 August 2010
References
1. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid
intima-media thickness and risk of stroke and myocardial infarction: the
Rotterdam Study. Circulation 1997, 96:1432-1437.
2. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ,
Rosamond WD, Evans G: Carotid wall thickness is predictive of incident
clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study.
American Journal of Epidemiology 2000, 151:478-487.
3. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr:
Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study
Collaborative Research Group. N Engl J Med 1999, 340:14-22.
4. Touboul PJ, Labreuche J, Vicaut E, Amarenco P, on behalf of the GENIC
Investigators: Carotid Intima-Media Thickness, Plaques, and Framingham
Risk Score as Independent Determinants of Stroke Risk. Stroke 2005,
36:1741-1745.
5. Yamasaki Y, Kodama M, Nishizawa H, Sakamoto K, Matsuhisa M, Kajimoto Y,
Kosugi K, Shimizu Y, Kawamori R, Hori M: Carotid intima-media thickness
in Japanese type 2 diabetic subjects: predictors of progression and
relationship with incident coronary heart disease. Diabetes Care 2000,
23:1310-1315.
6. Boissel JP, Collet JP, Moleur P, Haugh M: Surrogate endpoints: a basis for
a rational approach. Eur J Clin Pharmacol 1992, 43:235-244.
7. Bots ML, Palmer MK, Dogan S, Plantinga Y, Raichlen JS, Evans GW,
O’Leary DH, Grobbee DE, Crouse I Jr: Intensive lipid lowering may reduce
progression of carotid atherosclerosis within 12 months of treatment:
the METEOR study. J Intern Med 2009, 265(6):698-707.
8. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH,
Grobbee DE, Bots ML, for the METEOR Study Group: Effect of Rosuvastatin
on Progression of Carotid Intima-Media Thickness in Low-Risk
Individuals With Subclinical Atherosclerosis: The METEOR Trial. JAMA: The
Journal of the American Medical Association 2007, 297:1344-1353.
9. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA,
Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A,
Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F,
Zhu J: Effect of lower targets for blood pressure and LDL cholesterol on
atherosclerosis in diabetes: the SANDS randomized trial. JAMA: The
Journal of the American Medical Association 2008, 299:1678-1689.
10. Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H,
Matsuhisa M, Kosugi K, Hori M: Metformin or gliclazide, rather than
glibenclamide, attenuate progression of carotid intima-media thickness
in subjects with type 2 diabetes. Diabetologia 2004, 47:1906-1913.
11. Kodama M, Yamasaki Y, Sakamoto K, Yoshioka R, Matsuhisa M, Kajimoto Y,
Kosugi K, Ueda N, Hori M: Antiplatelet Drugs Attenuate Progression of
Carotid Intima-Media Thickness in Subjects with Type 2 Diabetes.
Thrombosis Research 2000, 97:239-245.
12. Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S: Metformin
attenuates progression of carotid arterial wall thickness in patients with
type 2 diabetes. Diabetes Res Clin Pract 2004, 64:225-228.
13. Fleiss JL: The design and analysis of clinical experiments. John Wiley and
sons, Inc, New York 1986.
14. Gepner AD, Korcarz CE, Aeschlimann SE, LeCaire TJ, Palta M, Tzou WS,
Stein JH: Validation of a carotid intima-media thickness border detection
program for use in an office setting. J Am Soc Echocardiogr 2006,
19:223-228.
15. Lim TK, Lim E, Dwivedi G, Kooner J, Senior R: Normal Value of Carotid
Intima-Media Thickness-A Surrogate Marker of Atherosclersosis:
Quantitative Assessment by B-Mode Carotid Ultrasound. Journal of the
American Society of Echocardiography 2008, 21:112-116.
16. Touboul PJ, Vicaut E, Labreuche J, Belliard JP, Cohen S, Kownator S, Pithois-
Merli I: Design, baseline characteristics and carotid intima-media
thickness reproducibility in the PARC study. Cerebrovasc Dis 2005,
19:57-63.
17. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD,
Sachara C, Pfutzner A: Pioglitazone decreases carotid intima-media
thickness independently of glycemic control in patients with type 2
diabetes mellitus: results from a controlled randomized study. Circulation
2005, 111:2525-2531.
18. Yokoyama H, Katakami N, Yamasaki Y: Recent advances of intervention to
inhibit progression of carotid intima-media thickness in patients with
type 2 diabetes mellitus. Stroke 2006, 37:2420-2427.
19. Hosomi N, Mizushige K, Ohyama H, Takahashi T, Kitadai M, Hatanaka Y,
Matsuo H, Kohno M, Koziol JA: Angiotensin-converting enzyme inhibition
with enalapril slows progressive intima-media thickening of the
common carotid artery in patients with non-insulin-dependent diabetes
mellitus. Stroke 2001, 32:1539-1545.
20. Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of
type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a
population-based study of 13,000 men and women with 20 years of
follow-up. Arch Intern Med 2004, 164:1422-1426.
21. Booth GL, Kapral MK, Fung K, Tu JV: Relation between age and
cardiovascular disease in men and women with diabetes compared with
non-diabetic people: a population-based retrospective cohort study.
Lancet 2006, 368:29-36.
22. Bonora E, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M,
Willeit J: Impaired glucose tolerance, Type II diabetes mellitus and
carotid atherosclerosis: prospective results from the Bruneck Study.
Diabetologia 2000, 43:156-164.
23. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M:
Carotid artery intima-media thickness in elderly patients with NIDDM
and in nondiabetic subjects. Stroke 1996, 27:1986-1992.
Lundby-Christensen et al. Cardiovascular Diabetology 2010, 9:40
http://www.cardiab.com/content/9/1/40
Page 6 of 724. Lee CD, Folsom AR, Pankow JS, Brancati FL: Cardiovascular events in
diabetic and nondiabetic adults with or without history of myocardial
infarction. Circulation 2004, 109:855-860.
25. de Groot E, van Leuven SI, Duivenvoorden R, Meuwese MC, Akdim F,
Bots ML, Kastelein JJ: Measurement of carotid intima-media thickness to
assess progression and regression of atherosclerosis. Nat Clin Pract
Cardiovasc Med 2008, 5:280-288.
26. Meuwese MC, de GE, Duivenvoorden R, Trip MD, Ose L, Maritz FJ,
Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH,
Schwocho LR, Stein EA: ACAT inhibition and progression of carotid
atherosclerosis in patients with familial hypercholesterolemia: the
CAPTIVATE randomized trial. JAMA: The Journal of the American Medical
Association 2009, 301:1131-1139.
27. Montauban van Swijndregt AD, De Lange EE, de Groot E, Ackerstaff RGA:
An in vivo evaluation of the reproducibility of intima-media thickness
measurements of the carotid artery segments using B-mode ultrasound.
Ultrasound in Medicine & Biology 1999, 25:323-330.
28. Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T,
Eckstein HH, Heemann U, Staessen JA: Association between carotid
diameter and the advanced glycation end product N-epsilon-
carboxymethyllysine (CML). Cardiovasc Diabetol 2009, 8:45.
29. Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M: The
estimated GFR, but not the stage of diabetic nephropathy graded by
the urinary albumin excretion, is associated with the carotid intima-
media thickness in patients with type 2 diabetes mellitus: a cross-
sectional study. Cardiovasc Diabetol 2010, 9:18.
30. Keech AC, Grieve SM, Patel A, Griffiths K, Skilton M, Watts GF, Marwick TH,
Groshens M, Celermajer DS: Urinary albumin levels in the normal range
determine arterial wall thickness in adults with Type 2 diabetes: a FIELD
substudy. Diabet Med 2005, 22:1558-1565.
31. Yokoyama H, Aoki T, Imahori M, Kuramitsu M: Subclinical atherosclerosis is
increased in type 2 diabetic patients with microalbuminuria evaluated
by intima-media thickness and pulse wave velocity. Kidney Int 2004,
66:448-454.
doi:10.1186/1475-2840-9-40
Cite this article as: Lundby-Christensen et al.: Carotid intima-media
thickness in individuals with and without type 2 diabetes: a
reproducibility study. Cardiovascular Diabetology 2010 9:40.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lundby-Christensen et al. Cardiovascular Diabetology 2010, 9:40
http://www.cardiab.com/content/9/1/40
Page 7 of 7